All In MedTech

FDA Clearance Tracker · P160053-S002

MagtraceTM and Sentimag(R) Magnetic Locatization System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 6, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P160053-S002
Device name
MagtraceTM and Sentimag(R) Magnetic Locatization System
Applicant location
Cambridge
Received
Aug 30, 2018
Decided
Dec 6, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160053

Device type

Device class
Class III

Every decision under product code PUV

FDA's approval statement

As written in FDA's record.

Approved to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure, in patients with breast cancer undergoing a mastectomy or lumpectomy. For patients undergoing lumpectomy, nipple sparing, nipple areolar sparing or skin sparing procedures, Magtrace is indicated to be injected only peritumorally.

Source documents

Other decisions for Endomagnetics Ltd.,

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.